Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials.

Jo-Hsuan WuSheng-Nan ChangTakashi NishidaBo-I KuoJou-Wei Lin

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2021)

With a treatment duration of 1-3 months, RKI showed effective IOP reduction noninferior to timolol as monotherapy and as adjunctive therapy. Our results suggested RKI be a reliable IOP control medication; however, its higher incidence of some ocular complications should be attended to.

Keyphrases

systematic review
optic nerve
risk factors
combination therapy
meta analyses
healthcare
open label
emergency department
protein kinase
smooth muscle
adverse drug
optical coherence tomography
bone marrow
replacement therapy
double blind